[1-deamino-4-cyclohexylalanine] arginine vasopressin: A potent and specific agonist for vasopressin V1b receptors

Endocrinology

Volumn 143, Issue 12, 2002, Pages 4655-4664

  Derick, S ^a   Cheng, L L ^b   Voirol, M J ^c   Stoev, S ^b   Giacomini, M ^c   Wo, N C ^d   Szeto, H H ^d   Mimoun, M Ben ^a   Andres, M ^a   Gaillard, R C ^c   Guillon, Gilles ^a   Manning, M ^b  

^a INSERM   (France)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN DERIVATIVE; ARGIPRESSIN[1 DEAMINO 4 CYCLOHEXYLALANINE]; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; KETAMINE; LIGAND; OXYTOCIN; OXYTOCIN RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN DERIVATIVE; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ADENOHYPOPHYSIS; AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDIURESIS; ARTICLE; BIOLOGICAL MODEL; CATECHOLAMINE RELEASE; CATTLE; CHROMAFFIN CELL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DRUG BINDING; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; MAMMAL; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; RECEPTOR AFFINITY; SPECIES;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ARGININE VASOPRESSIN; CATECHOLAMINES; CATTLE; CELLS, CULTURED; CHO CELLS; CHROMAFFIN SYSTEM; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; CRICETINAE; DIURESIS; FEMALE; GENE EXPRESSION; HUMANS; PITUITARY GLAND, ANTERIOR; RATS; RATS, WISTAR; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; TRANSFECTION;

EID: 0036892843     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220363     Document Type: Article

References (45)

1. Jard S 1998 In Zingg HH, Bourque CW, Bichet DG, eds. Vasopressin Receptors. A Historical Survey. New York: Plenum Press; vol 449:1-13
2. Guillon G, Grazzini E, Andrez M, Breton C, Trueba M, Serradeil-LeGal C, Boccara G, Derick S, Chouinard L, Gallo-Payet N 1998 Vasopressin: A potent autocrine/paracrine regulator of mammal adrenal functions. Endocr Res 24: 703-710
3. Gao ZY, Gerard M, Henquin JC 1992 Glucose- and concentration-dependence of vasopressin-induced hormone release by mouse pancreatic islets. Regul Pept 38:89-98
4. Manning PT, Schwartz D, Katsube NC, Holmberg SW, Needleman P 1985 Vasopressin-stimulated release of atriopeptin: Endocrine antagonists in fluid homeostasis. Science 229:395-397
5. Barberis C, Tribollet E 1996 Vasopressin and oxytocin receptors in the central nervous system. Crit Rev Neurobiol 10:119-154
6. 1b receptor antagonist J Pharmacol Exp Ther 300:1122-1130
7. Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Seyer R, Hibert M, Tribollet E, Manning M 1999 Molecular pharmacology of AVP and OT receptors and therapeutic potential. Drug News Perspect 12:279-298
8. Michell RH, Kirk CJ, Billah MM 1979 Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 7:861-865
9. Thibonnier M, Coles P, Thibonnier A, Shoham M 2000 The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 41:175-202
10. Jard S, Gaillard RC, Guillon G, Marie J, Schoenenberg P, Muller AF, Manning M, Sawyer WH 1986 Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol Pharmacol 30:171-177
11. Schwartz J, Derdowska I, Sobocinska M, Kupryszewski G 1991 A potent new synthetic analog of vasopressin with relative agonist specificity for the pituitary. Endocrinology 129:1107-1109
12. Manning M, Balaspiri L, Moehring J, Haldar, J, Sawyer WH 1976 Synthesis and some pharmacological properties of deamino(4-threonine, 8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin. J Med Chem 19:842-845
13. Sawyer WH, Acosta M, Balaspiri L, Judd J, Manning M 1974 Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity. Endocrinology 94:1106-1115
14. 9]OVT: A selective oxytocin receptor ligand. Eur J Pharmacol 147:197-207
15. 1a vasopressin receptor agonist of high affinity. Br J Pharmacol 135:1828-1836
16. Cotte N, Balestre MN, Phalipou S, Hibert M, Manning M, Barberis C, Mouillac B 1998 Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. J Biol Chem 273:29462-29468
17. Wilson SP, Viveros OH 1981 Primary culture of adrenal medullary chromaffin cells in a chemically defined medium. Exp Cell Res 133:159-169
18. Owen PJ, Plevin R, Boarder MR 1989 Characterization of bradykinin-stimulated release of noradrenaline from cultured bovine adrenal chromaffin cells. J Pharmacol Exp Ther 248:1231-1236
19. Guillon G, Trueba M, Joubert D, Grazzini E, Chouinard L, Cote M, Payet MD, Manzoni O, Barberis C, Robert M, Gallot-Payet N 1995 Vasopressin stimulates steroid secretion in human adrenal glands: Comparison with angiotensin-II effect. Endocrinology 136:1285-1295
20. Guillon G, Kirk CJ, Balestre MN 1986 Characterization of specific V1a vasopressin-binding sites on a rat mammary-tumour-cell line. Biochem J 240: 189-196
21. Butlen D, Guillon G, Rajerison RM, Jard S, Sawyer WH, Manning M 1978 Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: Effects of highly potent analogues and competitive inhibitors. Mol Pharmacol 14:1006-1017
22. Sawyer WH 1961 Biologic assays for oxytocin and vasopressin. Methods Med Res 9:210-219
23. Dekanski G 1952 Quantitative assay of vasopressin. Br J Pharmacol 7:567-572
24. Aizawa T, Yasuda N, Greet MA, Sawyer WH 1982 In vivo adrenocorticotropin-releasing activity of neurohypophyseal hormones and their analogs. Endocrinology 110:98-104
25. Chautard T, Spinedi E, Voirol MJ, Pralong FP, Gaillard RC 1999 Role of glucocorticoids in the response of the hypothalamo-corticotrope, immune and adipose systems to repeated endotoxin administration. Neuroendocrinology 69:360-369
26. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
27. Merrifield RB 1964 Solid-phase peptide synthesis. Biochemistry 2:1385-1390
28. Manning M, Balaspiri L, Acosta M, Sawyer WH 1973 Solid-phase synthesis of [deamino-4-valine]-8-D-arginine vasopressin (DVDAVP). A highly potent and specific antidiuretic agent possessing protracted effects. J Med Chem 16:975-978
29. Stoev S, Cheng L-L, Olma A, Klis WA, Manning M, Sawyer WH, Wo NC, Chan WY 1999 An investigation of position three in arginine vasopressin with aliphatic, aromatic, conformationally restricted, polar and charged amino acids. J Peptide Sci 5:141-153
30. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG 1954 The synthesis of oxytocin. J Am Chem Soc 76:3115-3121
31. Rivier J, Kaiser R, Galyean R 1978 Solid-phase synthesis of somatostatin and glucagon-selective analogs in gram quantities. Biopolymers 17:1927-1938
32. Manning M, Wuu TC, Baxter JWM 1968 The purification of synthetic oxytocin and a analogues by gel filtration on Sephadex G-15. J Chromatogr 38:396-398
33. 1b receptors. In: Martinez J, Fehrentz JA, eds. Peptides 2000. Paris: Editions Medicales et Scientifiques; 915-916
34. Gillies GE, Linton EA, Lowry PJ 1982 Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299:355-357
35. Grazzini E, Lodboerer AM, Perez-Martin A, Joubert D, Guillon G 1996 Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. Endocrinology 137:3906-3914
36. Ben Mimoun M, Derick S, Andres M, Guillon G, Wo NC, Chan WY, Stoev S, Cheng LL Manning M 2001 Affinities for rat V2 and V1a receptors reveal surprising species differences. In: Martinez J, Fehrentz JA, eds. Peptides 2000. Paris: Editions Medicales et Scientifiques; 589-590
37. Saito M, Tahara A, Sugimoto T 1997 1-Desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol 53:1711-1717
38. Guillon G, Balestre MN, Mouillac B, Berrada R, Kirk CJ 1987 Mechanisms of phospholipase C activation: A comparison with the adenylate cyclase system. Biochimie (Paris) 69:351-363
39. Lolait SJ, O'Carroll AM, Mahan LC, Felder CC, Button DC, Young WS 3rd, Mezey E, Brownstein MJ 1995 Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 92:6783-6787
40. Hernando F, Schools O, Lolait SJ, Burbach JP 2001 Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: Anatomical support for its involvement in the central effects of vasopressin. Endocrinology 142:1659-1668
41. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF 1994 Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60:436-444
42. Holsboer F 2000 The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501
43. van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA, De Wied D 1997 Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17:284-292
44. Aguilera G, Pham Q, Rabadan-Diehl C 1994 Regulation of pituitary vasopressin receptors during chronic stress: Relationship to corticotroph responsiveness. J Neuroendocrinol 6:299-304
45. 1b receptor mRNA during stress in the rat. J Neuroendocrinol 7: 903-910